Commentary|Podcasts|October 26, 2023

DCT Opportunities in Clinical Research

A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and more.

About the speaker


Edward Triebell is the Executive Director of Digital Health at Medical Research Network (MRN) and leads their strategy on empowering the use of digital technology in MRN’s Decentralized Clinical Trials services.

Mr. Triebell has been on the forefront of disruptive innovations in the development and application of digital technology for companies in the telecommunications, software, and healthcare industries. He started his career in design engineering and then transitioned into project engineering, program management, and sales eventually running global sales and marketing teams for technology focused enterprises, providing a wide lens on the requirements, development and launch of successful digital products and services.

For the past several years, Mr. Triebell has been involved in equity funded strategic roles. His most recent role pivoted an Internet of Things (IoT) software platform into an eCOA solution for successful acquisition by a CRO.

Within the healthcare industry, Mr. Triebell has been involved with programs including a telemedicine network for the Mayo Clinic network of hospitals to accomplish remote diagnosis and surgical treatments with high resolution imaging/videos, RFID solutions for patient tracking within Emergency Departments as well as audited tracking of patient biological samples and outsourcing radiological contouring for cancer treatments using a joint venture with China’s leading Cancer hospital.

Mr. Triebell earned his bachelor’s degree in electrical engineering and completed graduate coursework for his dual master’s degree in electrical engineering/engineering management from Florida Institute of Technology. He also completed an Executive Management program at the Wharton School of Business.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Pharmaceutical Executive Daily
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.